Dexamethasone intravitreal implant for treating diabetic macular oedema - guidance (TA349)

NICE Accredited

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
22 July 2015

Abstract

Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in July 2018. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.